Current options for the acute treatment and prophylaxis of hereditary angioedema

Laraib Tabba, Timothy J. Craig

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Over the past 3 years, the availability of targeted therapies, including C1-esterase inhibitors, bradykinin receptor antagonists and kallikrein inhibitors, have dramatically altered the treatment paradigm of hereditary angioedema. For acute attacks of hereditary angioedema, fresh frozen plasma have been replaced by first-line agents such as C1-esterase inhibitors (Berinert®, Cetor®, Cinryze® and Rhucin®), ecallantide (Kalbitor®) and icatibant (Firazyr®). Short-term prophylaxis is now generally limited to having C1-esterase inhibitors available for minor manipulations and administering a dose of either 20 U/kg or 1000 U prior to the procedures for longer and more traumatic procedures or androgens such as danazol 200 mg three-times daily 5-7 days before and 2 days post procedure or if nothing else is available FFP. Which ever drug is used on demand therapy should be available since no prophylaxis is 100% protective. For patients with recurrent attacks, those poorly controlled with androgens, or those who fail on-demand therapy for acute attacks, long-term prophylaxis should be considered with C1-esterase inhibitors while giving consideration to the high associated cost.

Original languageEnglish (US)
Title of host publicationCurrent and Emerging Options for Hereditary Angioedema Management
PublisherFuture Medicine Ltd.
Pages19-30
Number of pages12
ISBN (Electronic)9781780840208
ISBN (Print)9781780841106
DOIs
StatePublished - Aug 1 2012

Fingerprint

Complement C1 Inhibitor Protein
Hereditary Angioedemas
Androgens
Danazol
Kallikreins
Therapeutics
Costs and Cost Analysis
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Tabba, L., & Craig, T. J. (2012). Current options for the acute treatment and prophylaxis of hereditary angioedema. In Current and Emerging Options for Hereditary Angioedema Management (pp. 19-30). Future Medicine Ltd.. https://doi.org/10.2217/EBO.11.157
Tabba, Laraib ; Craig, Timothy J. / Current options for the acute treatment and prophylaxis of hereditary angioedema. Current and Emerging Options for Hereditary Angioedema Management. Future Medicine Ltd., 2012. pp. 19-30
@inbook{1e0d0fe78b37433d8a69f46e3ee94e15,
title = "Current options for the acute treatment and prophylaxis of hereditary angioedema",
abstract = "Over the past 3 years, the availability of targeted therapies, including C1-esterase inhibitors, bradykinin receptor antagonists and kallikrein inhibitors, have dramatically altered the treatment paradigm of hereditary angioedema. For acute attacks of hereditary angioedema, fresh frozen plasma have been replaced by first-line agents such as C1-esterase inhibitors (Berinert{\circledR}, Cetor{\circledR}, Cinryze{\circledR} and Rhucin{\circledR}), ecallantide (Kalbitor{\circledR}) and icatibant (Firazyr{\circledR}). Short-term prophylaxis is now generally limited to having C1-esterase inhibitors available for minor manipulations and administering a dose of either 20 U/kg or 1000 U prior to the procedures for longer and more traumatic procedures or androgens such as danazol 200 mg three-times daily 5-7 days before and 2 days post procedure or if nothing else is available FFP. Which ever drug is used on demand therapy should be available since no prophylaxis is 100{\%} protective. For patients with recurrent attacks, those poorly controlled with androgens, or those who fail on-demand therapy for acute attacks, long-term prophylaxis should be considered with C1-esterase inhibitors while giving consideration to the high associated cost.",
author = "Laraib Tabba and Craig, {Timothy J.}",
year = "2012",
month = "8",
day = "1",
doi = "10.2217/EBO.11.157",
language = "English (US)",
isbn = "9781780841106",
pages = "19--30",
booktitle = "Current and Emerging Options for Hereditary Angioedema Management",
publisher = "Future Medicine Ltd.",
address = "United Kingdom",

}

Tabba, L & Craig, TJ 2012, Current options for the acute treatment and prophylaxis of hereditary angioedema. in Current and Emerging Options for Hereditary Angioedema Management. Future Medicine Ltd., pp. 19-30. https://doi.org/10.2217/EBO.11.157

Current options for the acute treatment and prophylaxis of hereditary angioedema. / Tabba, Laraib; Craig, Timothy J.

Current and Emerging Options for Hereditary Angioedema Management. Future Medicine Ltd., 2012. p. 19-30.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Current options for the acute treatment and prophylaxis of hereditary angioedema

AU - Tabba, Laraib

AU - Craig, Timothy J.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Over the past 3 years, the availability of targeted therapies, including C1-esterase inhibitors, bradykinin receptor antagonists and kallikrein inhibitors, have dramatically altered the treatment paradigm of hereditary angioedema. For acute attacks of hereditary angioedema, fresh frozen plasma have been replaced by first-line agents such as C1-esterase inhibitors (Berinert®, Cetor®, Cinryze® and Rhucin®), ecallantide (Kalbitor®) and icatibant (Firazyr®). Short-term prophylaxis is now generally limited to having C1-esterase inhibitors available for minor manipulations and administering a dose of either 20 U/kg or 1000 U prior to the procedures for longer and more traumatic procedures or androgens such as danazol 200 mg three-times daily 5-7 days before and 2 days post procedure or if nothing else is available FFP. Which ever drug is used on demand therapy should be available since no prophylaxis is 100% protective. For patients with recurrent attacks, those poorly controlled with androgens, or those who fail on-demand therapy for acute attacks, long-term prophylaxis should be considered with C1-esterase inhibitors while giving consideration to the high associated cost.

AB - Over the past 3 years, the availability of targeted therapies, including C1-esterase inhibitors, bradykinin receptor antagonists and kallikrein inhibitors, have dramatically altered the treatment paradigm of hereditary angioedema. For acute attacks of hereditary angioedema, fresh frozen plasma have been replaced by first-line agents such as C1-esterase inhibitors (Berinert®, Cetor®, Cinryze® and Rhucin®), ecallantide (Kalbitor®) and icatibant (Firazyr®). Short-term prophylaxis is now generally limited to having C1-esterase inhibitors available for minor manipulations and administering a dose of either 20 U/kg or 1000 U prior to the procedures for longer and more traumatic procedures or androgens such as danazol 200 mg three-times daily 5-7 days before and 2 days post procedure or if nothing else is available FFP. Which ever drug is used on demand therapy should be available since no prophylaxis is 100% protective. For patients with recurrent attacks, those poorly controlled with androgens, or those who fail on-demand therapy for acute attacks, long-term prophylaxis should be considered with C1-esterase inhibitors while giving consideration to the high associated cost.

UR - http://www.scopus.com/inward/record.url?scp=84956745753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956745753&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.157

DO - 10.2217/EBO.11.157

M3 - Chapter

AN - SCOPUS:84956745753

SN - 9781780841106

SP - 19

EP - 30

BT - Current and Emerging Options for Hereditary Angioedema Management

PB - Future Medicine Ltd.

ER -

Tabba L, Craig TJ. Current options for the acute treatment and prophylaxis of hereditary angioedema. In Current and Emerging Options for Hereditary Angioedema Management. Future Medicine Ltd. 2012. p. 19-30 https://doi.org/10.2217/EBO.11.157